Introduction
============

Neovascular glaucoma (NVG) is a severe sequel of ocular ischemia due to various conditions including retinal vein occlusion, diabetic retinopathy, and ocular ischemic syndrome.[@b1-opth-11-1417]--[@b3-opth-11-1417] In southeast Asia, a study by Shen et al in Singapore showed that 20% of 150 subjects had secondary glaucoma, and 3.3% of those were diagnosed with NVG.[@b4-opth-11-1417] In Indonesia, a study by Artini and Dame in 2011 at Cipto Mangunkusumo Hospital found the incidence of NVG was up to 8% between 2005 and 2007.[@b5-opth-11-1417]

NVG poses tremendous challenge in its management. It is often difficult and unpredictable to control due to its resistance toward medications and surgery. Key factors in the treatment of NVG include management of the underlying ischemic condition by eliminating angiogenic stimuli through panretinal photocoagulation followed by intraocular pressure (IOP) control with antiglaucoma medications or surgery.[@b6-opth-11-1417],[@b7-opth-11-1417] Surgery is indicated in NVG with uncontrolled IOP with maximally tolerated antiglaucoma medications. Surgical modalities vary from filtering surgery with 5-fluorouracyl or mitomycin C as adjuvant, glaucoma drainage device (GDD) implantation, to cyclodestructive procedures. Filtering surgery and cyclodestructive procedures often fail to achieve high success rate;[@b1-opth-11-1417],[@b6-opth-11-1417],[@b8-opth-11-1417] thus, GDD implantation becomes the modality of choice in NVG, especially in patients that are irresponsive to medications.

Bevacizumab (Avastin; Genentech, South San Francisco, CA, USA) is a monoclonal vascular endothelial growth factor (VEGF) inhibitor which induces regression of iris neovascularization when administered through intravitreal or intracameral route.[@b9-opth-11-1417],[@b10-opth-11-1417] Bevacizumab induces regression of neovascularization within 6 weeks after injection, reduces IOP, and decreases complication rate after trabeculectomy in NVG.[@b4-opth-11-1417] Many studies have been published regarding the use of intravitreal bevacizumab (IVB) injection in conjunction with GDD implantation; however, evidence is still lacking on whether GDD implantation combined with IVB injection is beneficial for the treatment of NVG.

This retrospective study aimed to evaluate the efficacy of IVB injection with a wide range of GDD implantation in patients with NVG by comparing this procedure with GDD implantation alone in terms of visual acuity (VA), IOP, number of antiglaucoma medications, and surgical success rate.

Materials and methods
=====================

This study is a retrospective study based on a complete review of each patient's ophthalmological chart retrieved from medical records. Written informed consent according to the protocol conforming to the Declaration of Helsinki and approval from the Ethical Committee of Faculty of Medicine, Universitas Indonesia were waived. Institutional Review Board waiver was obtained and statement of patients' data confidentiality was submitted prior to the start of the study.

Inclusion criteria
------------------

This institutional retrospective study collected the medical records of patients admitted to the ophthalmology department of Cipto Mangunkusumo Kirana Hospital (Jakarta, Indonesia) diagnosed with NVG between January 2012 and December 2014. The diagnosis of NVG was made by glaucoma specialists in glaucoma clinic and defined as the presence of iris and/or anterior chamber angle neovascularization with elevated IOP (≥21 mmHg). Among a total of 74 consecutive eyes with NVG, only those who underwent GDD implantation were kept. Thirty nine eyes underwent GDD implantation which included Ahmed glaucoma valve (AGV), Baerveldt implant, and Keiki Mehta implant. Exclusion criteria were age ≥16 years and follow-up duration of \<3 months.

Surgical technique
------------------

Surgery was performed by 4 glaucoma specialists. IVB injection was administered along with GDD implantation using 1 cc syringe and 30G needle through pars plana 4 mm posterior from the limbus into the vitreous cavity with a dosage of 1.25 mg/0.05 cc. The standard procedures of GDD implantation were as follows. Fornix-based conjunctival pocket was created followed by dissection of Tenon's capsule. Implant plate was placed and secured to the sclera at the superotemporal quadrant. Anterior chamber entrance site was created using 23G needles. Implant tube was inserted through the path into the anterior chamber. Scleral allograft was used to cover the tube on the sclera surface. Conjunctiva and Tenon's capsule were sutured at the limbus. After repositioning of the conjunctiva, antibiotics were injected away from the surgical site. Patients were then discharged on levofloxacin and prednisolone 6 times per day.

Data collection
---------------

Data included age at the time of diagnosis, sex, etiology of NVG, affected eye, IOP measured by Goldmann applanation tonometry or Icare^®^ TA01i tonometer, VA presented in logMAR, number of antiglaucoma medications used, follow-up duration, and intraoperative IVB injection. Measurements of IOP were taken preoperatively and postoperatively at 1 month, 3 months, and at the last follow-up. VA was measured preoperatively and postoperatively at the final visit. VA of counting fingers was equivalent to 2.3 logMAR, hand movement was equivalent to 2.6 logMAR, light perception (LP) was 3.0 logMAR, and no light perception (NLP) was 4.0 logMAR.[@b11-opth-11-1417] All patients were under maximally tolerated antiglaucoma medications before surgery, except in cases of major contraindications. Surgical success was defined as stabilization of IOP between 6 and 21 mmHg with or without antiglaucoma medications, without the loss of LP. Surgical failure was defined as IOP \<6 mmHg or \>21 mmHg, deterioration of VA toward NLP, or the need for additional glaucoma surgeries.

Statistical analysis
--------------------

Statistical analysis and graphics were performed using IBM SPSS 20.0 (IBM Corporation, Armonk, NY, USA). The results were presented as mean ± SD or median (range) according to the distribution of the data, and percentages. Qualitative data were compared using chi-square or Fisher's exact test, and quantitative data using independent-samples *t*-test or Mann--Whitney test and paired-samples *t*-test or Wilcoxon test according to the distribution of data. The cumulative probability of surgical success was analyzed by Kaplan--Meier method and log-rank test was used to compare the calculated success rate. Statistical significance was defined as *P*\<0.05.

Results
=======

There were 44 cases from 41 patients with NVG who underwent GDD implantation between January 2012 and December 2014. Five patients had a follow-up period of \<3 months; thus, they were excluded from the study. Finally, a total of 39 eyes from 36 patients were analyzed.

Out of 39 eyes, 30 eyes underwent GDD implantation only (control group) while 9 eyes underwent GDD implantation in combination with IVB injection (IVB group). [Table 1](#t1-opth-11-1417){ref-type="table"} represents the demographic and baseline characteristics of both groups. No significant differences were observed in terms of age, gender distribution, involved eye, etiology, and follow-up period. Both groups also shared a similar proportion regarding type of implants, in which AGV implant was the most commonly used. VA, IOP, and number of antiglaucoma medications were also not significantly different between the two groups.

Comparison of VA, IOP, and number of medications at the final postoperative visit between groups is shown in [Table 2](#t2-opth-11-1417){ref-type="table"}. All three variables showed no significant difference between the control group and IVB group. In terms of surgical success rate, IVB group had a higher success rate compared to the control group, 66.7% and 56.7%, respectively. However, this difference was not proven to be significant (*P*=0.71). Within group comparison between preoperative and postoperative conditions of all variables can be seen in [Table 3](#t3-opth-11-1417){ref-type="table"}. Control group showed significant decrease in the final VA which was 2.3--2.6 logMAR (*P*\<0.01), whereas IVB group showed unchanged VA at 2.3 logMAR (*P*=0.24). Substantial changes of IOP and number of medications were observed in both groups.

IOP distribution at different follow-up times is shown in [Figure 1](#f1-opth-11-1417){ref-type="fig"}. Major decrease of IOP to \<21 mmHg was seen as early as 1 month postoperatively in both IVB and control groups. The IVB group tended to have lower IOP compared to the control group at 1 and 3 months of follow-up, although the differences were not proven to be statistically significant. IOP changes from 1 month to final follow-up also showed a tendency to be lower in both groups despite it being statistically insignificant.

In terms of GDD type, additional analysis was performed between all GDD implant types. There were no statistically significant differences between AGV implant, Baerveldt implant, and Keiki Mehta implant in terms of 1 month, 3 months, and final postoperative IOP (*P*-value =0.70, 0.19, and 0.78, respectively).

A comparison of Kaplan--Meier survival curve analysis between the two groups is presented in [Figure 2](#f2-opth-11-1417){ref-type="fig"}. The probability of success 37 months after surgery was 53.6% in the IVB group and 31.6% in the control group. The log-rank test revealed no significant difference between the groups (*P*=0.45).

Discussion
==========

Ischemia in more than half the retina causes tissue hypoxia which leads to expression and release of angiogenic factors, as seen in NVG. VEGF is one of major angiogenic factors involved. Accumulation of VEGF along with other angiogenic factors induces formation of iris neovascularization and anterior synechia leading to increased IOP.[@b2-opth-11-1417],[@b7-opth-11-1417]

GDD implantation becomes the first-line treatment alternative in NVG management because of its effectiveness and low postoperative complication rate.[@b2-opth-11-1417] Although it is considered effective, NVG itself is a risk factor toward failure after GDD implantation.[@b12-opth-11-1417] Currently, the choice between available implants (Ahmed, Baerveldt, etc) depends on surgeon's preference and experience without affecting final outcomes and complications.[@b13-opth-11-1417]

Recently, the use of anti-VEGF agents for the treatment of NVG has been found to be beneficial. Although its effectiveness is proven to be limited in a short period of time, administration of bevacizumab is proven to show benefits.[@b14-opth-11-1417] Besides, bevacizumab can be used in combination with GDD implantation in patients with NVG.[@b15-opth-11-1417]

The purpose of this study was to evaluate the outcomes of GDD implantation with and without the combination of IVB injection regarding VA, IOP, and number of antiglaucoma medications. Additionally, the potential of IVB injection toward surgical success rate was also assessed.

Bevacizumab seemed to have little effect on visual prognosis in eyes with NVG. In this study, no significant difference was observed regarding the final VA of both IVB group and control group. This finding was similar to other studies which stated that bevacizumab was not beneficial in terms of visual outcome.[@b7-opth-11-1417],[@b16-opth-11-1417] In this study, loss of LP was observed in 22.2% of cases in IVB group compared to 26.7% in the control group. Similar result was observed in a study by Sahyoun et al in which the rate of loss of LP was lower in IVB group.[@b7-opth-11-1417] Although IVB did not have the ability to improve vision, it seemed to be able to maintain VA. It is also shown in our study that the control group suffered significant visual deterioration while the IVB group did not at the final visit. A study by Kang et al showed that IVB might provide better VA up to 1 month postoperatively by reducing the rate of hyphema and macular edema.[@b17-opth-11-1417]

GDD implantation was effective in decreasing the IOP as seen in this study in which all cases had lower IOP until last follow-up. Final IOP was different between 3 types of GDD implants. IOP in the IVB group was slightly lower than that in the control group, 12.0 (2.0--49.0) and 16.3±10.3 mmHg, respectively. Recent studies reported that IVB injection, whether given intraoperatively or preoperatively, may contribute to reducing the IOP after surgery.[@b15-opth-11-1417],[@b18-opth-11-1417] IVB injection given as adjunctive treatment in recalcitrant NVG may affect the reversible part of synechia in anterior chamber angle and further reduce the IOP after GDD implantation.[@b17-opth-11-1417]

Surgical success rate in the IVB group was higher than the control group, though not statistically significant. Similar results were seen in other studies in which IVB resulted in a higher success rate although not proven significant.[@b17-opth-11-1417],[@b19-opth-11-1417] The transient nature of IVB might contribute to a lack of the improved probability in success, as postulated by Takihara et al.[@b18-opth-11-1417] Regression of iris neovascularization persists for 8--10 weeks after IVB injection but then returns to its previous condition within 6 months after administration.[@b20-opth-11-1417],[@b21-opth-11-1417] The accumulation and elevation of VEGF levels in aqueous humor and vitreous may further induce tissue fibrosis around the place which then leads to surgical failure.[@b19-opth-11-1417]

This study had several limitations. First, selection bias could not be avoided completely due to its retrospective nature. To address this bias, we compared the preoperative characteristics of both groups and found no significant differences. Second, the minimum of 3 months follow-up duration may be inadequate to obtain the true effect of IVB injection. However, the number of patients with a longer follow-up duration were too few to acquire statistical results. Further prospective and randomized studies with long-term follow-up would provide clearer results of the effect of intravitreal anti-VEGF in patients with NVG. Third, the lack of a standardized protocol of IVB injection in NVG especially regarding timing of administration may also contribute as a limitation in this study. The last and a major limitation to this study was the unbalanced number of subjects between the groups. Due to the design limitation of the study, we were unable to have a comparable number of subjects in each group. Therefore, it is rather difficult to draw a direct conclusion and it should be understood carefully.

Conclusion
==========

GDD implantation provided good outcomes in NVG management in terms of IOP control and reduction of antiglaucoma medications. GDD implantation combined with IVB injection might offer the potential in maintaining VA compared to GDD alone despite IOP control and number of medications remaining the same. Prospective study with a larger sample size and longer period of follow-up is warranted. IVB injection protocol should also be standardized to confirm efficacy and safety of this treatment modality.
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![IOP distribution in control group (30 eyes, blue line) and IVB group (9 eyes, green line) at various follow-up periods.\
**Notes:** IOP decreased at all time points compared with preoperative IOP in both groups. However, the differences of IOP between the groups were not statistically significant at any period. Error bars: 95% CI.\
**Abbreviations:** IVB, intravitreal bevacizumab; IOP, intraocular pressure; GDD, glaucoma drainage device; CI, confidence interval.](opth-11-1417Fig1){#f1-opth-11-1417}

![Cumulative probability of success after surgery in IVB group (9 eyes, green line) and control group (30 eyes, blue line) using Kaplan--Meier survival curve analysis.\
**Note:** Log-rank test revealed no significant difference in the survival time between groups.\
**Abbreviation:** IVB, intravitreal bevacizumab.](opth-11-1417Fig2){#f2-opth-11-1417}

###### 

Baseline demographic and clinical characteristics of the two study groups

                                   Control group (n=30)   IVB group (n=9)    *P*-value
  -------------------------------- ---------------------- ------------------ --------------------------------------------------
  Age (years)                      55.5±15.8              52.5±16.3          0.64[a](#tfn2-opth-11-1417){ref-type="table-fn"}
  Sex, n (%)                                                                 
   Male                            16 (53.3%)             4 (44.4%)          0.72[b](#tfn3-opth-11-1417){ref-type="table-fn"}
   Female                          14 (46.7%)             5 (55.6%)          
  Etiology, n (%)                                                            
   Diabetic retinopathy            17 (56.7%)             6 (66.7%)          1.00[b](#tfn3-opth-11-1417){ref-type="table-fn"}
   Retinal vein occlusion          4 (13.3%)              1 (11.1%)          
   Others                          9 (30.0%)              2 (22.2%)          
  Implant type, n (%)                                                        
   Ahmed glaucoma valve            13 (43.3%)             5 (55.6%)          0.89[b](#tfn3-opth-11-1417){ref-type="table-fn"}
   Baerveldt implant               10 (33.3%)             2 (22.2%)          
   Keiki Mehta implant             7 (23.3%)              2 (22.2%)          
  Follow-up period (months)        9.0 (4.0--37.0)        15.0 (4.0--37.0)   0.33[c](#tfn4-opth-11-1417){ref-type="table-fn"}
  Initial visual acuity (logMAR)   2.3 (0.2--3.0)         2.3 (0.5--3.0)     0.74[c](#tfn4-opth-11-1417){ref-type="table-fn"}
  Initial IOP (mmHg)               49.3±14.7              45.1±13.0          0.42[a](#tfn2-opth-11-1417){ref-type="table-fn"}
  Initial number of medications    2.0 (2.0--3.0)         2.0 (2.0--3.0)     0.43[c](#tfn4-opth-11-1417){ref-type="table-fn"}

**Notes:** Data presented as mean ± standard deviation or median (min-max) according to the distribution of the data.

Student's *t*-test;

Fisher's exact test;

Mann--Whitney test.

**Abbreviations:** IVB, intravitreal bevacizumab; IOP, intraocular pressure; SD, standard deviation.

###### 

Comparison of final postoperative clinical conditions between the two groups

                                 Control group (n=30)   IVB group (n=9)    *P*-value
  ------------------------------ ---------------------- ------------------ --------------------------------------------------
  Final visual acuity (logMAR)   2.6 (0.2--4.0)         2.3 (0.4--4.0)     0.97[a](#tfn7-opth-11-1417){ref-type="table-fn"}
  Final IOP (mmHg)               16.3±10.3              12.0 (2.0--49.0)   0.40[a](#tfn7-opth-11-1417){ref-type="table-fn"}
  Final number of medications    1.0 (0--4.0)           1.0 (0--2.0)       0.57[a](#tfn7-opth-11-1417){ref-type="table-fn"}
  Success rate, n (%)                                                      
   Success                       17 (56.7%)             6 (66.7%)          0.71[b](#tfn8-opth-11-1417){ref-type="table-fn"}
   Failure                       13 (43.3%)             3 (33.3%)          

**Notes:** Data presented as mean ± standard deviation or median (min-max) according to the distribution of the data.

Mann--Whitney test;

Fisher's exact test.

**Abbreviations:** IVB, intravitreal bevacizumab; IOP, intraocular pressure.

###### 

Comparison of preoperative and postoperative clinical conditions within each group

                                 Control group (n=30)   IVB group (n=9)                                                                                                 
  ------------------------------ ---------------------- ----------------- --------------------------------------------------------- ---------------- ------------------ ---------------------------------------------------------
  Final visual acuity (logMAR)   2.3 (0.2--3.0)         2.6 (0.2--4.0)    \<**0.01**[a](#tfn11-opth-11-1417){ref-type="table-fn"}   2.3 (0.5--3.0)   2.3 (0.4--4.0)     0.24[a](#tfn11-opth-11-1417){ref-type="table-fn"}
  Final IOP (mmHg)               49.3±14.7              16.3±10.3         \<**0.01**[b](#tfn12-opth-11-1417){ref-type="table-fn"}   45.1±13.0        12.0 (2.0--49.0)   **0.01**[a](#tfn11-opth-11-1417){ref-type="table-fn"}
  Final number of medications    2.0 (2.0--3.0)         1.0 (0--4.0)      \<**0.01**[a](#tfn11-opth-11-1417){ref-type="table-fn"}   2.0 (2.0--3.0)   1.0 (0--2.0)       \<**0.01**[a](#tfn11-opth-11-1417){ref-type="table-fn"}

**Notes:** Data presented as mean ± standard deviation or median (min-max) according to the distribution of the data. Data in bold indicates statistically significant difference between the two conditions (initial and final) of each group (control and IVB group).

Wilcoxon test;

paired *t*-test.

**Abbreviations:** IVB, intravitreal bevacizumab; IOP, intraocular pressure.
